Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
29
Today In Oncology
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
F-SHARP Trial Evaluates Focal Salvage Brachytherapy and Genomic Risk Stratification in Recurrent Prostate Cancer
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo